

				11
			1	
		2022	1	11
				2022
61				
		A	100,000,000	2022
3	22			493,189,000
		424,181,006		86.01%,
		69,007,994		13.99%
9			36	
		76,357,580		11.7939%
	2022		10	3
		17,620,980		2023
			9	25
			2023	9
			23	

	2023	5	16		2022	
<2022						>
	10	3		2022	12	31
						493,189,000
			147,956,700			641,145,700
2023	5	29				
			641,145,700			
				2021		2021
						2023
	7	17				
2023	6-38			2023	7	16
						76
						14,523,894.00
6,287,400.00						8,236,494.00
			647,433,100.00			647,433,100.00
				2023	7	20

“

12

1

12

12

36

2

”

“

12

1

12

12

36

2

6

”

“ 1 / / /

2 / / 5%

3 / / /

4 / / / /

”

1		5,408,000	0.8353%	5,408,000	0
2		4,275,700	0.6604%	2,704,000	1,571,700
3		13,520,000	2.0882%	13,520,000	0
4		5,408,000	0.8353%	5,408,000	0
5		5,408,000	0.8353%	5,408,000	0
6		26,012,480	4.0178%	26,012,480	0

1		76,357,580	36

11


1

(本页无正文, 为《海通证券股份有限公司关于和元生物技术有限公司首次公开发行部分限售股上市流通的核查意见》签字盖章页)

保荐代表人签名:



陈恒瑞



张子慧

